Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote "FOR" the Transaction With Xeris

Stock Information for Strongbridge Biopharma plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Strongbridge Biopharma plc

Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.